Over the past two decades, the Southeast has seen an increasing number of startups and venture capital investments. This maturation of the regional startup ecosystem has been spurred by an increase in notable exits and an increased focus and commitment from universities, state legislatures, local government and local financiers.
Annually, SEBIO recognizes best in class deals by the region’s biomedical companies in five categories: Public Offering, Strategic Acquisition, Strategic Investment, Venture Funding and Initial Venture Funding. The winners of the 2018 SEBIO awards will be announced at the 20th Annual SEBIO conference on November 14, during lunch. Please join us in congratulating these companies for their achievements and honoring the winners at our lunch.
The finalists for this year’s awards are:
Liquidia raised $50 M in its initial public offering, which it will use to advance its innovative, particle-engineering drug delivery products.
Adial raised $7.3 M in its initial public offering, which it will use to advance AD04, a therapeutic which can be used in the treatment of alcohol use disorder (AUD).
Concurrent with a $21 M raise from current and new investors, Innovate completed its reverse merger with Monster Digital and is now publicly traded (INNT).
K2M – Leesburg, VA
K2M develops and manufactures a variety of implants, instruments, and disposables for the treatment of spinal pathologies. This Virginia-based company announced in August its acquisition by Stryker for $1.4 billion.
Cartiva developed a synthetic cartilage implant for treating arthritis at the base of the great toe. Cartiva was acquired this year by Wright Medical for $435 M.
Avanos Medical (Formerly Halyard Health) – Alpharetta, GA
Halyard sold its Surgical & Infection Control business to Owens & Minor for $710mm to finance continued growth of its core medical device business, with the company rebranded as Avanos Medical in mid-2018 and remains in Alpharetta.
Lacerta Therapeutics, a clinical stage gene therapy company, has secured $30 M in equity investment from Sarepta Therapeutics.
Richmond-based HedgePath Pharmaceuticals secured $1.6 M in funding from Mayne Pharma to advance its SUBA-Itraconazole clinical and regulatory program.
Humacyte secured a $150 M strategic investment from Fresenius Medical, the world’s largest dialysis company, to commercialize the product for dialysis applications.
Surterra Wellness, a medical marijuana company, has raised over $65 M in Series C funding this year.
Precision Biosciences’ has secured $110 M in Series B funding to pursue clinical deployment of its immuno-oncology, off-the-shelf CAR-T product.
Soluble Systems (now Solsys Medical) – Newport News, VA
Soluble Systems raised $ 19 M in Series E funding to further their wound care product development.
Locus Biosciences has raised $19 M in Series A funding to develop its next generation CRISPR-Cas platform for precision antimicrobials.
Morphogenesis has raised $16 M in Series A funding to advance their immune system-based cancer therapy, ImmuneFX.
StrideBio has secured $15.7 M in Series A funding to continue development of their gene therapy programs.